A statement released earlier today by Piper Jaffray about Array Biopharma (NASDAQ:ARRY) bumps the target price to $10.00
- Updated: September 26, 2016
Boasting a price of $3.65, Array Biopharma (NASDAQ:ARRY) traded 63.84% higher on the day. With the last stock price close up 77.50% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Array Biopharma has recorded a 50-day average of $3.56 and a two hundred day average of $3.37. Volume of trade was up over the average, with 64,656,332 shares of ARRY changing hands over the typical 2,000,060
Piper Jaffray bumped up the target of Array Biopharma (NASDAQ:ARRY) to $10.00 stating a potential upside of 1.74%.
On Monday August 29, 2016, Jefferies & Co released a statement for Array Biopharma (NASDAQ:ARRY) bumped up the target price from $6.00 to $7.00 that suggested an upside of 1.05%.
Recent Performance Chart
Array Biopharma has with a one year low of $2.38 and a one year high of $6.15 and has a market capitalization of $0.
A total of 7 analysts have released a report on Array Biopharma. Four analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $8.14.
General Company Details For Array Biopharma (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.